Period of time： 2014年1期
Publisher： Informa Healthcare
Founded in： 1996
Total resources： 42
ISSN： 1472-8214
Subject： R9 Pharmacy
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Expert Opinion on Emerging Drugs,volume 9,issue 1
Menu
HIV entry and fusion inhibitors
Expert Opinion on Emerging Drugs,volume 9,issue 1 , Vol. 9, Iss. 1, 2004-05 , pp.
Access to resources
Recommend
Potential therapeutic targets for neurokinin-1 receptor antagonists
Expert Opinion on Emerging Drugs,volume 9,issue 1 , Vol. 9, Iss. 1, 2004-05 , pp.The clinical application of monoclonal antibody therapies in renal transplantation
By Dhanireddy Kiran K,Xu He,Mannon Roslyn B,Hale Douglas A,Kirk Allan D in (2004)
Expert Opinion on Emerging Drugs,volume 9,issue 1 , Vol. 9, Iss. 1, 2004-05 , pp.Advances in pharmacotherapy for tobacco dependence
By Foulds Jonathan,Burke Michael,Steinberg Michael,Williams Jill M,Ziedonis Douglas M in (2004)
Expert Opinion on Emerging Drugs,volume 9,issue 1 , Vol. 9, Iss. 1, 2004-05 , pp.Emerging treatments in acute myeloid leukaemia
Expert Opinion on Emerging Drugs,volume 9,issue 1 , Vol. 9, Iss. 1, 2004-05 , pp.Emerging drugs in pancreatic cancer
By Ducreux Michel,Boige Valérie,Malka David in (2004)
Expert Opinion on Emerging Drugs,volume 9,issue 1 , Vol. 9, Iss. 1, 2004-05 , pp.Emerging drugs for head and neck cancer
By Rhee John C,Khuri Fadlo R,Shin Dong M in (2004)
Expert Opinion on Emerging Drugs,volume 9,issue 1 , Vol. 9, Iss. 1, 2004-05 , pp.Emerging DNA topoisomerase inhibitors as anticancer drugs
Expert Opinion on Emerging Drugs,volume 9,issue 1 , Vol. 9, Iss. 1, 2004-05 , pp.Histone modification enzymes: novel targets for cancer drugs
By Kristeleit Rebecca,Stimson Lindsay,Workman Paul,Aherne Wynne in (2004)
Expert Opinion on Emerging Drugs,volume 9,issue 1 , Vol. 9, Iss. 1, 2004-05 , pp.
Previous
Next